Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
|Videos|August 3, 2021
The 3 Insights Guiding John O'Brien and NPC
John M. O’Brien, PharmD, MPH, newly appointed President and CEO of the National Pharmaceutical Council, discusses the 3 main insights that have guided him throughout his career.
Advertisement
Pharmacy Times interviewed John M. O'Brien, PharmD, MPH, on his new role as president and CEO of the National Pharmaceutical Council (NPC).
In this discussion, O'Brien defines the 3 central insights that have guided him over the years and that NPC is committed to: put the patient at the center, follow the science, and engage in constructive dialogue with everyone.
Advertisement
Related to this article
A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.
Isatuximab plus Iberdomide maintenance helps MRD-positive myeloma patients turn MRD-negative after transplant, with manageable safety.
Insulin efsitora alfa-gobe (Onswik; Eli Lilly and Company) is designed to deliver steady basal insulin levels over a full 7-day duration.
Vallerie McLaughlin, MD, explains why the ERS update strongly recommends sotatercept for patients with pulmonary arterial hypertension (PAH) who don't reach low-risk status on initial therapy.
Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
Renal benefit appeared only in patients with albuminuria in a 75,455-person BMJ analysis, whereas sulfonylureas signaled faster decline without it.
Authors of a pharmacist-directed transitions-of-care study discuss what drives pneumococcal vaccine hesitancy and how pharmacists can build systematic vaccine screening into inpatient workflows.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
2
After 180 Years, Multiple Myeloma Gets a Definition of Cure
3
Teclistamab-Daratumumab Intensification Achieves 73% MRD-Negative CR Rate in High-Risk Multiple Myeloma
4
Tec-Dara Cuts Death Risk 78% Without Raising Fatal Toxicity
5